Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.
For T2DM patients with heart or kidney risks, GLP-1 receptor agonists are a top choice. They help lower blood sugar, promote significant weight loss by reducing visceral fat, and protect the heart and kidneys. Discuss options like weekly injections or oral formulations with your doctor.
GoodSupportsHIGH confidence
The remarkable ectopic/visceral fat depletion, which might be attributed to the anorexigenic and insulinotropic characteristics of these incretin-based medications... can lead to favorable metabolic consequences including improved hepatic insulin sensitivity/glycemic control and cardiovascular/renal outcomes.
Why this rating
Supported by major CVOTs and meta-analyses.
Source
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
Jingjing Zhu et al. · Current Atherosclerosis Reports · 2023
DOI 10.1007/s11883-023-01181-4
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT-2 inhibitors reduce cardiovascular and renal risks in type 2 diabetes patients by promoting glucose and sodium excretion, which triggers fatty acid beta-oxidation and depletes ectopic/visceral fat.Good
- Energy-restricted diets have limited efficacy in reducing body fat and preventing cardiovascular events in T2DM compared to metabolic surgery or newer pharmacological interventions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →